AsianScientist (Mar. 26, 2012) – Netherlands-based QIAGEN and the Bio-X Center of Shanghai Jiao Tong University have signed an agreement to open a joint translational medicine lab in Shanghai.
The lab is the first of its kind between QIAGEN and a major research institution in China, and is a key milestone in the company’s expansion in key emerging markets.
“Translational medicine is quickly becoming the future of medicine by applying basic research to develop clinical diagnostics and therapies that prevent disease and optimize patient care,” said Dr. Victor Shi, Asia Pacific President of QIAGEN.
“Through this agreement with the Bio-X Center we can leverage our leading positions as a solutions provider in biological research, drug discovery and personalized healthcare to help develop better diagnostics and therapies for the Chinese people.”
QIAGEN will provide the Center with Pyromark Q24MDx and QIAcube instruments and related products for a variety of research projects that include biomarker validation and analysis.
“Translational Medicine aims to transform basic research results into clinically applicable practices. The trend of translational medicine is unstoppable and I think both scientists and policy makers should adapt this new concept as quick as possible and work together to improve human health” said Professor He Lin, Director of the Bio-X Center at Shanghai Jiao Tong University and a member of the Chinese Academy of Sciences.
——
Source: QIAGEN.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
